Oteseconazole
Kathryn Dzintars, Pharm.D., BCPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Oteseconazole (Vivjoa) is an FDA-approved azole antifungal to reduce the incidence of recurrent vulvovaginal Candidiasis (RVVC) in women not of child-bearing potential.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.